ERBB2 and breast carcinoma: However, the objective response rate (ORR) of trastuzumab is lower in HER2-positive GC than in HER2-positive breast cancer (16% vs. 26%) [8, 29], and although trastuzumab treatment improves PFS and OS in HER2-positive GC, intrinsic or acquired resistance to trastuzumab is a significant clinical problem [15].